Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.52 |
| ▸ | ITGAV | P06756 | 13/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 12/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7405983 | 0.90 | ITGB3 (0.52) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7405357 | 0.88 | ITGAV (0.49) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7401670 | 0.85 | ITGB3 (0.70) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7401078 | 0.84 | ITGB3 (0.74) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7406637 | 0.80 | ITGB3 (0.52) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7982239 | 0.80 | ITGAV (0.53) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7403054 | 0.80 | ITGB3 (0.47) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7405451 | 0.79 | ITGB3 (0.52) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7969330 | 0.79 | ITGB3 (0.52) | ITGB3ITGAVITGA2BITGB1ITGA5 | |
| SCHEMBL7400646 | 0.78 | ITGB3 (0.53) | ITGB3ITGAVITGA2BITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0828737-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-18 | — | — | EP | claimed |
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | claimed |
| US-6214834-B1 | ANGIOGENESIS INHIBITORS; ANTIINFLAMMATORY AGENTS; ANTICANCER AGENTS | DUPONT PHARMACEUTICALS COMPANY | 2001-04-10 | — | — | US | disclosed |
| EP-0828737-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-03-18 | — | — | EP | disclosed |
| WO-1996037492-A1 | ISOXAZOLINE AND ISOXAZOLE DERIVATIVES AS INTEGRIN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-11-28 | — | — | WO | disclosed |